BUDhealth® Patient-Derived Tumor Organoid Drug Sensitivity Test & NGS Service - ACCURATE | Technology Platform of Organoid in Scientific Research, Drug Development and Precision Medicine

Home
About Us
Technology
Clinical Service
New Drug R&D Service
Products
News
- Press Releases

Double Accuracy, Double Benefits

BUDhealth® Patient-Derived Tumor Organoid Drug Sensitivity Test & NGS Service

This service combines the PDTO drug screening results and NGS data, and provides scientific references from different dimensions to assist clinicians setting up individualized treatment strategies.

Procedures

Applications

Neoadjuvant Chemotherapy

Adjuvant Chemotherapy after Surgery

Difficult-decision Settings

Advanced Cancer Stages

Clinical Benefits

Selecting the most effective drug by screening potential therapeutic drugs of targeted mutations.

Satisfying the unmet needs of NGS, allow screening of chemotherapy and combination therapy.

Message Board

Please select the type of service

attachment（Each file size limit is 20MB，file format jpg,png,gif,jpeg,bmp,pdf,mp3,mp4,doc,docx,csv,xls,xlsx,ppt,pptx,zip,7z,rar,tar）

Click or drag file to upload

Get code 60s